Holen Sie sich die Stockscreener-App
1.3908
1.06%
-0.0192
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.41
Offen:
$1.38
24-Stunden-Volumen:
3.49M
Relative Volume:
0.86
Marktkapitalisierung:
$264.30M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-0.656
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
-14.42%
1M Leistung:
-17.94%
6M Leistung:
-23.35%
1J Leistung:
-51.56%
1-Tages-Spanne:
$1.37
$1.43
1-Wochen-Bereich:
$1.35
$1.67
52-Wochen-Spanne:
$1.35
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.395 | 264.30M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
163.26 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.32 | 17.38B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.87 | 14.05B | 612.78M | -86.37M | -62.91M | -0.87 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion Appoints Robert E. Hoffman as New Director - TipRanks
Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewswire
Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director - Stock Titan
Esperion stock hits 52-week low at $1.46 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $1.46 amid challenges - Investing.com India
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive: Esperion Reveals Next-Gen Drug Pipeline at Major Healthcare Conference - Stock Titan
BB Biotech AG Reduces Stake in Esperion Therapeutics Inc - GuruFocus
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia - Nasdaq
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia - MarketScreener
Esperion Aligns with U.S. Food and Drug Administration to - GlobeNewswire
Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid - StreetInsider.com
FDA Backs Esperion's Breakthrough Move into Pediatric Cholesterol Treatment - Stock Titan
Esperion Therapeutics chief commercial officer sells $3,617 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CFO sells $5,242 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CEO Koenig sells $19,622 in stock By Investing.com - Investing.com South Africa
Esperion Therapeutics CEO Koenig sells $19,622 in stock - Investing.com
Esperion Therapeutics CFO sells $5,242 in stock - Investing.com India
Esperion Therapeutics chief commercial officer sells $3,617 in stock - Investing.com
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Esperion stock hits 52-week low at $1.55 amid market challenges - Investing.com Australia
Esperion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
Q3 Earnings Forecast for ESPR Issued By HC Wainwright - Defense World
Esperion Therapeutics, Inc. SEC 10-K Report - TradingView
Esperion Therapeutics Inc. (ESPR) reports earnings - Quartz
Brokers Set Expectations for ESPR Q1 Earnings - Defense World
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts - Defense World
Esperion stock target holds at $4 on JMP’s optimistic outlook By Investing.com - Investing.com South Africa
Esperion stock target holds at $4 on JMP’s optimistic outlook - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright - Defense World
Esperion Therapeutics: Q4 Earnings Snapshot - Barchart
Esperion stock hits 52-week low at $1.58 amid challenges By Investing.com - Investing.com Australia
Esperion Therapeutics Reports Strong Revenue Growth in 2024 - TipRanks
Esperion Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Esperion Therapeutics stock surges over 9% on strong Q4 results - Investing.com
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Esperion Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Esperion Therapeutics Q4 Loss Narrows - Nasdaq
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Esperion Therapeutics stock surges over 9% on strong Q4 results By Investing.com - Investing.com Canada
ESPERION THERAPEUTICS Earnings Results: $ESPR Reports Quarterly Earnings - Nasdaq
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Esperion Therapeutics Inc-Aktie (ESPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Warren Eric | Chief Commercial Officer |
Mar 18 '25 |
Sale |
1.49 |
2,433 |
3,618 |
370,326 |
| Koenig Sheldon L. | President and CEO |
Mar 18 '25 |
Sale |
1.50 |
13,047 |
19,623 |
1,571,962 |
0.09%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):